Snowden Capital Advisors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $721K | Buy |
5,738
+346
| +6% | +$43.5K | 0.02% | 626 |
|
|
2025
Q1 | $596K | Sell |
5,392
-557
| -9% | -$61.6K | 0.02% | 663 |
|
|
2024
Q4 | $812K | Buy |
5,949
+82
| +1% | +$11.2K | 0.03% | 580 |
|
|
2024
Q3 | $676K | Sell |
5,867
-4,404
| -43% | -$507K | 0.02% | 641 |
|
|
2024
Q2 | $1.41M | Sell |
10,271
-100
| -1% | -$13.8K | 0.04% | 411 |
|
|
2024
Q1 | $1.43M | Sell |
10,371
-461
| -4% | -$63.6K | 0.04% | 412 |
|
|
2023
Q4 | $1.43M | Buy |
10,832
+641
| +6% | +$84.5K | 0.05% | 350 |
|
|
2023
Q3 | $1.15M | Buy |
10,191
+67
| +0.7% | +$7.54K | 0.05% | 382 |
|
|
2023
Q2 | $955K | Buy |
10,124
+5,227
| +107% | +$493K | 0.03% | 469 |
|
|
2023
Q1 | $496K | Buy |
4,897
+78
| +2% | +$7.9K | 0.02% | 734 |
|
|
2022
Q4 | $576K | Sell |
4,819
-631
| -12% | -$75.4K | 0.02% | 644 |
|
|
2022
Q3 | $578K | Buy |
5,450
+1,291
| +31% | +$137K | 0.03% | 592 |
|
|
2022
Q2 | $405K | Buy |
+4,159
| New | +$405K | 0.02% | 727 |
|
|
2021
Q4 | – | Sell |
-3,717
| Closed | -$356K | – | 2102 |
|
|
2021
Q3 | $356K | Buy |
3,717
+843
| +29% | +$80.9K | 0.02% | 629 |
|
|
2021
Q2 | $280K | Buy |
+2,874
| New | +$280K | 0.01% | 734 |
|